RARE – ultragenyx pharmaceutical inc. (US:NASDAQ)
Stock Stats
News
4/25
04:30 pm
rare
Low
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
4/24
01:38 pm
rare
Low
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at TD Cowen from $59.00 to $61.00. They now have a "buy" rating on the stock.
4/22
08:09 am
rare
Low
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $77.00 price target on the stock.
4/19
04:30 pm
rare
Medium
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
4/16
01:19 pm
rare
Medium
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study [Yahoo! Finance]
2/15/2024
04:01 pm
RARE
5.8%
BEAT
11/2/2023
04:05 pm
RARE
6.1%
MISS
8/3/2023
04:00 pm
RARE
-8.8%
MISS
5/4/2023
04:01 pm
RARE
3.1%
MISS
4/22
08:09 am
Initiates
Outperform
Royal Bank of Canada
Low
2.9%
4/22
08:09 am
Initiates
Outperform
Royal Bank of Canada
Low
2.9%
4/22
05:40 am
Initiates
Outperform
RBC Capital
Low
2.9%
4/22
05:40 am
Initiates
Outperform
RBC Capital
Low
2.9%
4/17
01:19 pm
Reiterates
Neutral
Neutral
Wedbush
Low
-0.1%
4/26
04:34 pm
rare
Medium
Form ARS Ultragenyx Pharmaceutica For: Dec 31
4/26
04:33 pm
rare
Medium
Form DEFA14A Ultragenyx Pharmaceutica
4/26
04:32 pm
rare
Medium
Form DEF 14A Ultragenyx Pharmaceutica For: Jun 18
4/19
04:36 pm
rare
Medium
Form 4 Ultragenyx Pharmaceutica For: Apr 18 Filed by: Crombez Eric
4/18
06:06 pm
rare
Low
Form 4 Ultragenyx Pharmaceutica For: Apr 16 Filed by: Huizenga Theodore Alan
Show more
Top News Gainers
1/9 Ultragenyx Announces Positive Topline Cohort 3 Results and Improved Longer-Term Cohort 2 Results from Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency 23.4%
3/13 Form 4 Ultragenyx Pharmaceutica For: Mar 12 Filed by: KAKKIS EMIL D 10.2%
1/13 Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO) 8.1%
3/9 Ultragenyx to Present at Barclays Global Healthcare Conference 7.7%
4/2 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $75.00 price target on the stock. 6.6%
6/17 Ultragenyx Expands Leadership Team and Promotes Erik Harris to Chief Commercial Officer 6.5%
3/31 REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder 5.7%
7/17 Form 4 Ultragenyx Pharmaceutica For: Jul 16 Filed by: Pinion John Richard 5.1%
9/11 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 4.4%
4/17 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 4.2%
Top News Decliners
3/16 GeneTx and Ultragenyx Announce First Patient Dosed in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome -21.2%
9/4 Form 8-K Ultragenyx Pharmaceutica For: Sep 04 -13.3%
3/6 Form 8-K Ultragenyx Pharmaceutica For: Mar 03 -9.3%
8/1 Form 8-K Ultragenyx Pharmaceutica For: Aug 01 -9.0%
5/7 Form 10-Q Ultragenyx Pharmaceutica For: Mar 31 -7.0%
8/27 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.9%
3/6 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.8%
10/29 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -6.1%
11/5 Q3/2019 9/30/2019 EPS -1.960 ZacksConsensus -1.710 ActVsEst (0.250) - Miss -5.9%
9/3 GeneTx and Ultragenyx Announce Orphan Drug Designation and Rare Pediatric Disease Designation for GTX-102 -5.8%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3